Form 4 for AKTX Akari Therapeutics Plc

Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-14 · accession 0000950170-24-128190 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-11-18	2024-11-14	AKTX	Patel Samir Rashmikant	Dir	A - Grant	—	+1.40B	4.82B	+41%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares, par value $0.0001 per share	2024-11-14	A	A	1,404,622,000	—	4,816,117,500	I PranaBio Investments LLC	—	—	(F1) The Ordinary Shares may be represented by American Depositary Shares ("ADSs"), each of which currently represents 2,000 Ordinary Shares. (F2) This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. ("Peak Bio"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer ("Merger Sub"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Peak Bio (each, a "Peak Share") was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") ADSs. (F3) Represents the number of Ordinary Shares acquired by the Reporting Person from the exchange of Peak Shares held by the Reporting Person at the Effective Time in accordance with the Exchange Ratio.